Literature DB >> 16304429

Considerations for adult cancer survivors.

André Tichelli1, Gérard Socié.   

Abstract

With improvements in outcome, increased numbers of adult cancer patients survive free of their primary malignancy. Today, about 60% of adult patients diagnosed with cancer will survive 5 years after diagnosis. Therefore, immediate survival is no longer the sole concern. The aim of the cancer treatment now is to cure a patient's underlying disease and, at the same time, to minimize the incidence of post-treatment complications and ensure the best possible long term quality of life. The long time span between initial therapy and late effects, the multiple factors influencing cancer-related health risk and the unknown effect of treatment on normal aging are common characteristics of late effects. While the treatment strategy for a cancer patient depends widely on the type and extension of the disease, considerations for a long-term survivor depend much more on the type of treatment applied, age of the patient, and the patient's general health status as well as his or her familial and social integration. We discuss, based on the most recent knowledge, some typical examples of late effects in cancer survivors and the practical recommendations that could assist practitioner and patient decision about appropriate healthcare for specific clinical circumstances.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16304429     DOI: 10.1182/asheducation-2005.1.516

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  7 in total

1.  Cardiac autonomic functioning is impaired among allogeneic hematopoietic stem cell transplantation survivors: a controlled study.

Authors:  G Deuring; A Kiss; J P Halter; J R Passweg; P Grossman
Journal:  Bone Marrow Transplant       Date:  2016-07-04       Impact factor: 5.483

Review 2.  Long term physical sequelae after adult-onset cancer.

Authors:  Sophie D Fosså; Rena Vassilopoulou-Sellin; Alv A Dahl
Journal:  J Cancer Surviv       Date:  2007-12-04       Impact factor: 4.442

Review 3.  Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.

Authors:  Lois B Travis; Sophie D Fossa; Howard D Sesso; Robert D Frisina; David N Herrmann; Clair J Beard; Darren R Feldman; Lance C Pagliaro; Robert C Miller; David J Vaughn; Lawrence H Einhorn; Nancy J Cox; M Eileen Dolan
Journal:  J Natl Cancer Inst       Date:  2014-03-12       Impact factor: 13.506

Review 4.  Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research.

Authors:  Joanne W Elena; Lois B Travis; Naoko I Simonds; Christine B Ambrosone; Rachel Ballard-Barbash; Smita Bhatia; James R Cerhan; Patricia Hartge; Rebecca S Heist; Lawrence H Kushi; Timothy L Lash; Lindsay M Morton; Kenan Onel; John P Pierce; Leslie L Robison; Julia H Rowland; Deborah Schrag; Thomas A Sellers; Daniela Seminara; Xiao Ou Shu; Nancy E Thomas; Cornelia M Ulrich; Andrew N Freedman
Journal:  J Natl Cancer Inst       Date:  2012-11-28       Impact factor: 13.506

Review 5.  Anti-cancer Therapy Leads to Increased Cardiovascular Susceptibility to COVID-19.

Authors:  Caroline Lozahic; Helen Maddock; Hardip Sandhu
Journal:  Front Cardiovasc Med       Date:  2021-04-23

6.  Multimorbidity and cancer outcomes: a for more research.

Authors:  Henrik Toft Sørensen
Journal:  Clin Epidemiol       Date:  2013-11-01       Impact factor: 4.790

7.  PPI in research: a reflection from early stage researchers.

Authors:  Alice M Biggane; Maria Olsen; Paula R Williamson
Journal:  Res Involv Engagem       Date:  2019-11-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.